Clinical trial tests promising CAR T-cell therapy for lupus - Summary - MDSpire

Clinical trial tests promising CAR T-cell therapy for lupus

UCI Health has launched a groundbreaking clinical trial for a next-generation CAR T-cell therapy.

  • By

  • January 13, 2026

  • 1 min

Share

Objective:

To investigate the efficacy of FT819, a novel CAR T-cell therapy, in providing long-term remission for patients with moderate to severe systemic lupus erythematosus unresponsive to standard treatments.

Key Findings:
  • FT819 therapy shows promise in achieving symptom reversal.
  • One participant experienced significant improvement after nearly two decades of severe lupus.
Interpretation:

The early results suggest that FT819 could be a viable alternative for lupus patients who have not responded to conventional therapies.

Limitations:
  • The trial is in its early stages, and further research is needed to confirm long-term efficacy and safety.
Conclusion:

FT819 CAR T-cell therapy may represent a breakthrough in lupus treatment, potentially offering hope for patients with severe disease.

Original Source(s)

Clinical trial tests promising CAR T-cell therapy for lupus

  • by

  • January 13, 2026

Related Content

Obturator neuropathy from SLE lymphadenopathy: an interdisciplinary diagnostic challenge

SSc May Be Linked to Subtle Cognitive Changes

Cross-sectional study finds domain-specific differences and higher anxiety without global impairment.

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.